Showing 5231-5240 of 5644 results for "".
- iSTAR Medical’s MINIject Shows Consistent Results at 18-Month Follow-Up in First-in-Human Trial (STAR-I)https://modernod.com/news/istar-medicals-miniject-shows-consistent-results-at-18-month-follow-up-in-first-in-human-trial-star-i/2476718/iSTAR Medical SA announced consistent 18-month results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial for the MINIject device in a standalone setting. These results confirm the stability and sustained performance of MINIject beyond the first year, according to a compan
- Bausch + Lomb Announces US Launch Of Ocuvite Eye Performance Vitaminshttps://modernod.com/news/bausch-lomb-announces-us-launch-of-ocuvite-eye-performance-vitamins/2476714/Bausch + Lomb announced the US launch of Ocuvite Eye Performance vitamins, which were formulated with seven nutrients that help strengthen the macula. The nutrients protect the eye from stressors such as sun light and blue light emitted from digital devices. These nutrients include lutein
- Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-license-agreement-with-aura-biosciences-for-suprachoroidal-space-microinjector/2479566/Clearside Biomedical announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space (SCS) Microinjector to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choro
- ProQR: RNA Therapy Has Potential to Restore Vision in Patients With Usher Syndromehttps://modernod.com/news/proqr-rna-therapy-has-potential-to-restore-vision-in-patients-with-usher-syndrome/2479570/Usher syndrome is an inherited retinal degeneration that affects hearing, balance, and vision. Usher syndrome caused by USH2A mutations is one of the most common causes of retinitis pigmentosa (RP) with syndromic features. Currently there is no treatment for the sensory deficits caused by Usher s
- EyeSouth Establishes Presence in Alabama Through Affiliation with Montgomery Eye Physicianshttps://modernod.com/news/eyesouth-establishes-presence-in-alabama-through-affiliation-with-montgomery-eye-physicians/2476711/EyeSouth Partners has announced that it has completed an affiliation with Montgomery Eye Physicians and Prescription Eyewear. The affiliation will be EyeSouth’s first in Alabama. Terms of the deal were not disclosed. EyeSouth is an eye care-focused management services organization.
- Small Percentage of Ophthalmologists Perform Large Proportion of Intravitreal Anti-VEGF Injectionshttps://modernod.com/news/small-percentage-of-ophthalmologists-perform-large-proportion-of-intravitreal-anti-vegf-injections/2476712/Three percent of ophthalmologists perform 17% to 31% of all anti-vascular endothelial growth factor (VEGF) injections in the U.S., depending on the agent used, according to new findings, as reported by Reuters. “More important
- Nicox Signs Agreement for NCX 4251 in China with Ocumension Therapeutics for Up to €12 Millionhttps://modernod.com/news/nicox-signs-agreement-for-ncx-4251-in-china-with-ocumension-therapeutics-for-up-to-e12-million/2476710/Nicox SA and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product candidate, NCX 4251—currently in a phase 2 trial in the United States in patients with acute exacerbations of blepharitis—for a territo
- Low-Cost Retinal Scanner Could Help Prevent Blindness Worldwidehttps://modernod.com/news/low-cost-retinal-scanner-could-help-prevent-blindness-worldwide/2476705/Biomedical engineers at Duke University have developed a low-cost, portable optical coherence tomography (OCT) scanner that promises to bring the vision-saving technology to underserved regions throughout the United States and abroad, according to a university news release. Thanks to a red
- BlephEx Asserts Claims of Patent Infringement and False Advertising Against Myco Industrieshttps://modernod.com/news/blephex-asserts-claims-of-patent-infringement-and-false-advertising-against-myco-industries/2476700/BlephEx, creator of the BlephEx device and eyelid cleaning procedure, announced that it has asserted claims of willful patent infringement and false advertising against Myco Industries and John R
- DORC Announces FDA Acceptance of Orphan NDA for Brilliant Blue G Ophthalmic Solutionhttps://modernod.com/news/dorc-announces-fda-acceptance-of-orphan-nda-for-brilliant-blue-g-ophthalmic-solution/2476701/DORC has announced that it has received notification from the FDA that their new drug application (NDA) for Brilliant Blue G ophthalmic solution has been accepted for review. The proposed indication for Brillia